Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT.
Autoimmune blistering disorder
Bullous pemphigoid
Dupilumab
Oral corticosteroids
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
05 Mar 2024
05 Mar 2024
Historique:
received:
21
12
2023
accepted:
31
01
2024
medline:
6
3
2024
pubmed:
6
3
2024
entrez:
5
3
2024
Statut:
aheadofprint
Résumé
Bullous pemphigoid (BP) is a rare, autoimmune, blistering skin disease associated with high disease burden, profoundly decreased quality of life and increased morbidity. Emerging evidence supports an important role for type 2 inflammation in disease pathogenesis. Current management relies on topical and/or systemic corticosteroids, non-selective immunosuppressants and antibiotics with anti-inflammatory properties, which are all limited by side effects and toxicities. Therefore, targeted, efficacious and safe therapies are needed. Dupilumab blocks the shared receptor component for interleukin (IL)-4 and IL-13, key and central drivers of type 2 inflammation. Several reports of patients successfully treated with dupilumab have been published; however, dupilumab has not been formally assessed in a double-blind, placebo-controlled trial. We report the design of LIBERTY-BP ADEPT, a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of dupilumab in adults with BP. LIBERTY-BP ADEPT comprises a 35-day screening, 52-week treatment and 12-week follow-up period. Approximately 98 adults aged 18-90 years with moderate-to-severe BP are being enrolled at 51 sites on 4 continents and randomized 1:1 to subcutaneous dupilumab or placebo every 2 weeks. All participants will receive concomitant oral corticosteroids (OCS). The primary endpoint is the proportion of patients achieving complete remission off steroid therapy at week 36. Key secondary endpoints include total cumulative OCS dose to week 36, percent change and proportion of patients with ≥ 4-point reduction in the weekly average of daily Peak Pruritus Numerical Rating Scale from baseline to week 36 and percent change in Bullous Pemphigoid Area Index score from baseline to week 36. The trial results will provide evidence on whether the efficacy and safety of dupilumab support its use as a potential novel treatment approach for BP and will provide new insights into the role of type 2 inflammation in BP pathogenesis. ClinicalTrials.gov identifier NCT04206553.
Sections du résumé
BACKGROUND
BACKGROUND
Bullous pemphigoid (BP) is a rare, autoimmune, blistering skin disease associated with high disease burden, profoundly decreased quality of life and increased morbidity. Emerging evidence supports an important role for type 2 inflammation in disease pathogenesis. Current management relies on topical and/or systemic corticosteroids, non-selective immunosuppressants and antibiotics with anti-inflammatory properties, which are all limited by side effects and toxicities. Therefore, targeted, efficacious and safe therapies are needed. Dupilumab blocks the shared receptor component for interleukin (IL)-4 and IL-13, key and central drivers of type 2 inflammation. Several reports of patients successfully treated with dupilumab have been published; however, dupilumab has not been formally assessed in a double-blind, placebo-controlled trial.
OBJECTIVES
OBJECTIVE
We report the design of LIBERTY-BP ADEPT, a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of dupilumab in adults with BP.
METHODS
METHODS
LIBERTY-BP ADEPT comprises a 35-day screening, 52-week treatment and 12-week follow-up period. Approximately 98 adults aged 18-90 years with moderate-to-severe BP are being enrolled at 51 sites on 4 continents and randomized 1:1 to subcutaneous dupilumab or placebo every 2 weeks. All participants will receive concomitant oral corticosteroids (OCS).
PLANNED OUTCOMES
UNASSIGNED
The primary endpoint is the proportion of patients achieving complete remission off steroid therapy at week 36. Key secondary endpoints include total cumulative OCS dose to week 36, percent change and proportion of patients with ≥ 4-point reduction in the weekly average of daily Peak Pruritus Numerical Rating Scale from baseline to week 36 and percent change in Bullous Pemphigoid Area Index score from baseline to week 36.
CONCLUSION
CONCLUSIONS
The trial results will provide evidence on whether the efficacy and safety of dupilumab support its use as a potential novel treatment approach for BP and will provide new insights into the role of type 2 inflammation in BP pathogenesis.
CLINICAL TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov identifier NCT04206553.
Identifiants
pubmed: 38443648
doi: 10.1007/s12325-024-02810-3
pii: 10.1007/s12325-024-02810-3
doi:
Banques de données
ClinicalTrials.gov
['NCT04206553']
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. Crown.
Références
Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2007;156(2):352–6.
pubmed: 17223877
doi: 10.1111/j.1365-2133.2006.07646.x
Persson MSM, Begum N, Grainge MJ, Harman KE, Grindlay D, Gran S. The global incidence of bullous pemphigoid: a systematic review and meta-analysis. Br J Dermatol. 2022;186(3):414–25.
pubmed: 34480482
doi: 10.1111/bjd.20743
Kridin K, Ludwig RJ. The growing incidence of bullous pemphigoid: overview and potential explanations. Front Med (Lausanne). 2018;5:220.
pubmed: 30177969
doi: 10.3389/fmed.2018.00220
Verheyden MJ, Bilgic A, Murrell DF. A systematic review of drug-induced pemphigoid. Acta Derm Venereol. 2020;100(15):adv00224.
Moro F, Fania L, Sinagra JLM, Salemme A, Di Zenzo G. Bullous pemphigoid: trigger and predisposing factors. Biomolecules. 2020;10(10):1432.
pubmed: 33050407
pmcid: 7600534
doi: 10.3390/biom10101432
Mul VE, van Geest AJ, Pijls-Johannesma MC, et al. Radiation-induced bullous pemphigoid: a systematic review of an unusual radiation side effect. Radiotherapy Oncol. 2007;82(1):5–9.
doi: 10.1016/j.radonc.2006.11.014
Joly P, Baricault S, Sparsa A, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol. 2012;132(8):1998–2004.
pubmed: 22418872
doi: 10.1038/jid.2012.35
Jung M, Kippes W, Messer G, Zillikens D, Rzany B. Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence. J Am Acad Dermatol. 1999;41(2 Pt 1):266–8.
pubmed: 10426901
doi: 10.1016/S0190-9622(99)70061-7
Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJP, West J. Bullous pemphigoid and pemphigus vulgaris—incidence and mortality in the UK: population-based cohort study. BMJ. 2008;337(7662): a180.
pubmed: 18614511
doi: 10.1136/bmj.a180
Bernard P, Antonicelli F. Bullous pemphigoid: a review of its diagnosis, associations and treatment. Am J Clin Dermatol. 2017;18(4):513–28.
pubmed: 28247089
doi: 10.1007/s40257-017-0264-2
Kouris A, Platsidaki E, Christodoulou C, et al. Quality of life, depression, anxiety and loneliness in patients with bullous pemphigoid. A case control study. An Bras Dermatol. 2016;91(5):601–3.
Wang EQ, Castrillón Velásquez MA, Murrell DF. The effects of autoimmune blistering diseases on work productivity: a review. Int J Womens Dermatol. 2018;4(3):131–8.
pubmed: 30175214
pmcid: 6116828
doi: 10.1016/j.ijwd.2017.11.001
Briand C, Gourier G, Poizeau F, et al. Characteristics of pruritus in bullous pemphigoid and impact on quality of life: a prospective cohort study. Acta Derm Venereol. 2020;100(18):adv00320.
Miyamoto D, Santi CG, Aoki V, Maruta CW. Bullous pemphigoid. An Bras Dermatol. 2019;94(2):133–46.
pubmed: 31090818
pmcid: 6486083
doi: 10.1590/abd1806-4841.20199007
della Torre R, Combescure C, Cortés B, et al. Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort. Br J Dermatol. 2012;167(5):1111–7.
Chen X, Zhang Y, Luo Z, et al. Prognostic factors for mortality in bullous pemphigoid: a systematic review and meta-analysis. PLoS ONE. 2022;17(4): e0264705.
pubmed: 35427358
pmcid: 9012347
doi: 10.1371/journal.pone.0264705
Seidman JS, Eichenfield DZ, Orme CM. Targeting type 2 inflammation for treatment of bullous pemphigoid. J Dermatol Skin Sci. 2020;2(1):29–33.
Kalowska M, Ciepiella O, Kowalewski C, Demkow U, Schwartz RA, Wozniak K. Enzyme-linked immunoassay index for anti-NC16a IgG and IgE auto-antibodies correlates with severity and activity of bullous pemphigoid. Acta Dem Venereol. 2016;96(2):191–6.
doi: 10.2340/00015555-2101
Russo R, Cozzani E, Gasparini G, Parodi A. Targeting interleukin 4 receptor α: a new approach to the treatment of cutaneous autoimmune bullous diseases? Dermatol Ther. 2020;33(1): e13190.
pubmed: 31863534
pmcid: 7154653
doi: 10.1111/dth.13190
Garcovitch S, Maurelli M, Gisondi P, Peris K, Yosipovitch G, Girolomoni G. Pruritus as a distinctive feature of type 2 inflammation. Vaccines (Basel). 2021;9(3):303.
doi: 10.3390/vaccines9030303
Feliciani C, Joly P, Jonkman MF, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol. 2015;172(4):867–77.
pubmed: 25827742
doi: 10.1111/bjd.13717
Joly P, Roujeau J-C, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321–7.
pubmed: 11821508
doi: 10.1056/NEJMoa011592
Kirtschig G, Middleton P, Bennet C, Murell DF, Wojnarowska F, Khumalo NP. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2010;(10):CD002292.
Venning VA, Taghipour K, Mohd Mustapa MF, Highet AS, Kirtschig G. British Association of Dermatologists’ guidelines for the management of bullous pemphigoid 2012. Br J Dermatol. 2012;167(6):1200–14.
pubmed: 23121204
doi: 10.1111/bjd.12072
Khalid SN, Khan ZA, Ali MH, Almas T, Khedro T, Nagarajan VR. A blistering new era for bullous pemphigoid: a scoping review of current therapies, ongoing clinical trials, and future directions. Ann Med Surg (Lond). 2021;70: 102799.
pubmed: 34540212
pmcid: 8435812
doi: 10.1016/j.amsu.2021.102799
Fichel F, Barbe C, Joly P, et al. Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study. JAMA Dermatol. 2014;150(1):25–33.
pubmed: 24226428
doi: 10.1001/jamadermatol.2013.5757
Gaies E, Jebabli N, Trabelsi S, et al. Methotrexate side effects: review article. J Drug Metabol Toxicol. 2012;3(4):123–5.
doi: 10.4172/2157-7609.1000125
Hall RP 3rd, Streilein RD, Hannah DL, et al. Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients. J Invest Dermatol. 2013;133(12):2786–8.
pubmed: 23732750
doi: 10.1038/jid.2013.236
Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320–32.
pubmed: 23237497
doi: 10.1016/S0140-6736(12)61140-4
Fairley JA, Baum CL, Brandt DS, Messingham KAN. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol. 2009;123(3):704–5.
pubmed: 19152970
pmcid: 4784096
doi: 10.1016/j.jaci.2008.11.035
Le Floc’h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188–204.
pubmed: 31838750
doi: 10.1111/all.14151
Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A. 2014;111:5147–52.
pubmed: 24706858
pmcid: 3986150
doi: 10.1073/pnas.1323896111
Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A. 2014;111:5153–8.
pubmed: 24706856
pmcid: 3986188
doi: 10.1073/pnas.1324022111
Hamilton JD, Harel S, Swanson BN, et al. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021;51(7):915–31.
pubmed: 34037993
pmcid: 8362102
doi: 10.1111/cea.13954
Koskeridis F, Evangelos E, Ntzani EE, Kostikas K, Tsabouri S. Treatment with dupilumab in patients with atopic dermatitis: systematic review and meta-analysis. J Cutan Med Surg. 2022;26(6):613–21.
pubmed: 36214355
doi: 10.1177/12034754221130969
Silverberg JI, Yosipovitch G, Simpson EL, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO1 and SOLO2, AD ADOL and CHRONOS. J Am Acad Dermatol. 2020;82(6):1328–36.
pubmed: 32135208
doi: 10.1016/j.jaad.2020.02.060
Yosipovitch G, Mollanazar N, Ständer S, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med. 2023;29(5):1180–90.
pubmed: 37142763
pmcid: 10202800
doi: 10.1038/s41591-023-02320-9
Geba GP, Li D, Xu M, et al. Attenuating the atopic march: meta-analysis of the dupilumab atopic dermatitis database for incident allergic events. J Allergy Clin Immunol. 2023;151(3):756–66.
pubmed: 36084766
doi: 10.1016/j.jaci.2022.08.026
Siegfried EC, Cork MJ, Boguniewicz M, et al. Dupilumab treatment reduces total IgE levels in patients 6 months and older with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2023;151(2 Suppl):AB149, Poster No. 456.
Maurer M, Casale T, Saini S, et al. Dupilumab significantly reduces itch and hives in patients with chronic spontaneous urticaria: results from a phase 3 trial (LIBERTY-CSU CUPID Study A). J Allergy Clin Immunol. 2022;149(2 Suppl):AB312.
Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. N Engl J Med. 2022;387(25):2317–30.
pubmed: 36546624
doi: 10.1056/NEJMoa2205982
Domingo C, Maspero JF, Castro M, et al. Dupilumab efficacy in steroid-dependent severe asthma by baseline oral corticosteroid dose. J Allergy Clin Immunol Pract. 2022;10(7):1835–43.
pubmed: 35398549
doi: 10.1016/j.jaip.2022.03.020
Silverberg JI, Lynde CW, Abuabara K, et al. Efficacy and safety of dupilumab maintained in adults ≥ 60 years of age with moderate-to-severe atopic dermatitis: analysis of pooled data from four randomized clinical trials. Am J Clin Dermatol. 2023;24(3):469–83.
pubmed: 36808602
pmcid: 10195762
doi: 10.1007/s40257-022-00754-4
Patruno C, Fabbrocini G, Longo G, et al. Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real-life observational study. Am J Clin Dermatol. 2021;22(4):581–6.
pubmed: 33725337
doi: 10.1007/s40257-021-00597-5
Kaye A, Gordon SC, Deverapalli SC, Her MJ, Rosmarin D. Dupilumab for the treatment of recalcitrant bullous pemphigoid. JAMA Dermatol. 2018;154(10):1225–6.
pubmed: 30140849
doi: 10.1001/jamadermatol.2018.2526
Seyed Jafari SM, Feldmeyer L, Bossart S, Simon D, Schlapbach C, Borradori L. Case report: combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid. Front Immunol. 2021;11: 611549.
pubmed: 33584689
pmcid: 7879677
doi: 10.3389/fimmu.2020.611549
Saleh M, Reedy M, Torok H, Weaver J. Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature. Dermatol Online J. 2021;27(4):13030/qt0dv3f9h6.
Abdat R, Waldman RA, de Bedout V, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series. J Am Acad Dermatol. 2020;83(1):46–52.
pubmed: 32179082
doi: 10.1016/j.jaad.2020.01.089
Zhang Y, Xu Q, Chen L, et al. Efficacy and safety of dupilumab in moderate-to-severe bullous pemphigoid. Front Immunol. 2021;12: 738907.
pubmed: 34721404
pmcid: 8552038
doi: 10.3389/fimmu.2021.738907
Murrell DF, Daniel BS, Joly P, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol. 2012;66(3):479–85.
pubmed: 22056920
doi: 10.1016/j.jaad.2011.06.032
Topp J, Apfelbacher C, Ständer S, Augustin M, Blome C. Measurement properties of patient-reported outcome measures for pruritus: an updated systematic review. J Invest Dermatol. 2022;142(2):343–54.
pubmed: 34339743
doi: 10.1016/j.jid.2021.06.032
Yosipovitch G, Reaney M, Mastey V, et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761–9.
pubmed: 30729499
pmcid: 6850643
doi: 10.1111/bjd.17744
Wijayanti A, Zhao CY, Boettiger D, et al. The reliability, validity and responsiveness of two disease scores (BPDAI and ABSIS) for bullous pemphigoid: which one to use? Acta Derm Venereol. 2017;97(1):24–31.
pubmed: 27244117
doi: 10.2340/00015555-2473
Patsatsi A, Kyriakou A, Pavlitou-Tsiontsi A, Giannakou A, Sotiriadis D. Association of autoantibodies to BP180 with disease activity in Greek patients with bullous pemphigoid. Clin Dev Immunol. 2012;2012: 854795.
pubmed: 23227089
pmcid: 3514843
doi: 10.1155/2012/854795
Sebaratnam DF, Hanna AM, Chee SN, et al. Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire. JAMA Dermatol. 2013;149(10):1186–91.
pubmed: 23925444
doi: 10.1001/jamadermatol.2013.4972
Tjokrowidjaja A, Daniel BS, Frew JW, et al. The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease Br J Dermatol. 2013;169(5):1000–6. Erratum in Br J Dermatol. 2014;170(2):481–3.
Ferries L, Gillibert A, Duvert-Lehembre S, et al. Sensitivity to change and correlation between the autoimmune bullous disease quality-of-life questionnaires ABQOL and TABQOL, and objective severity scores. Br J Dermatol. 2020;183(5):944–5.
pubmed: 32374931
doi: 10.1111/bjd.19173
Yang B, Chen G, Yang Q, et al. Reliability and validity of the Chinese version of the autoimmune bullous disease quality of life (ABQOL) questionnaire. Health Qual Life Outcomes. 2017;15(1):31.
pubmed: 28153023
pmcid: 5290597
doi: 10.1186/s12955-017-0594-z
Saleh MA, Zaraa I, Doss N, Saleh NA, Murrell DF. Assessment of the quality of life of Egyptian and Tunisian autoimmune bullous diseases’ patients using an Arabic version of the autoimmune bullous disease quality of life and the treatment of autoimmune bullous disease quality of life questionnaires. An Bras Dermatol. 2019;94(4):399–404.
pubmed: 31644610
pmcid: 7007032
doi: 10.1590/abd1806-4841.20197198
Teimourpour A, Hedayat K, Salarvand F, et al. Autoimmune Bullous Disease Quality of Life (ABQoL) questionnaire: validation of the translated Persian version in pemphigus vulgaris. Int J Womens Dermatol. 2020;6(4):306–10.
pubmed: 33015292
pmcid: 7522916
doi: 10.1016/j.ijwd.2020.03.043
Patsatsi A, Kokolios M, Kyriakou A, et al. Quality of life in Greek patients with autoimmune bullous diseases assessed with ABQOL and TABQOL indexes. Acta Derm Venereol. 2017;97(9):1145–7.
pubmed: 28660281
doi: 10.2340/00015555-2737
Kalinska-Bienias A, Jakubowska B, Kowalewski C, Murrell DF, Wozniak K. Measuring of quality of life in autoimmune blistering disorders in Poland. Validation of disease-specific Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaires. Adv Med Sci. 2017; 62(1):92–6.
Worm M, Simpson EL, Thaçi D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(2):131–43.
pubmed: 31876900
doi: 10.1001/jamadermatol.2019.3617
Silverberg JI, Yang F, Alemao E, et al. The risk of adverse events in US bullous pemphigoid patients treated with oral corticosteroids. Oral presentation at the 25th World Congress of dermatology; Singapore; July 3–8, 2023.
Persson MSM, Harman KE, Thomas KS, et al. Long-term oral prednisolone exposure in primary care for bullous pemphigoid: population-based study. Br J Gen Pract. 2021;71(713):e904–11.
pubmed: 34607796
pmcid: 8510692
doi: 10.3399/BJGP.2020.0870
Cole EF, DeGrazia T, Sun Y, Liu Y, Feldman RJ. Assessing disease outcome measures in bullous pemphigoid on standard-of-care therapies. JID Innov. 2021;1(4): 100050.
pubmed: 34909747
pmcid: 8659387
doi: 10.1016/j.xjidi.2021.100050